Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be ready

On September 14, the FDA set aside four hours and invited more than 80 speakers to consider how psychedelic therapies might work in regulated settings. The discussion reflected growing interest from regulators, physicians, patients, and veterans’ organizations in how these potential treatments may offer relief to those living with mental illness. But it also revealed a gap beyond rescheduling or reclassification: the infrastructure needed to deliver these…